


Vertex Sandbox > Pages > Type 1 diabetes

Longer-term data for VX-880 T1D program announced at EASD



Caleigh Findley

Published Oct 4, 2023 (Edited Oct 4, 2023) • 2 min read



EASD 59th Annual Meeting

We announced longer-term data for our VX-880 program targeting type 1 diabetes at the European Association of the Study of Diabetes Annual Meeting

Each year, the [European Association for the Study of Diabetes](#) (EASD) hosts a meeting to bring together leading experts in the diabetes space. As one of the largest diabetes-related conferences in the world, the meeting consistently hosts more than 1,200 talks and presentations providing the latest diabetes research updates.

This week, our type 1 diabetes (T1D) team at Vertex was thrilled to announce longer-term data from our VX-880 program at EASD. You can read our press release to learn more about the announcement [here](#). This builds upon the [data recently presented](#) at the American Diabetes Association in June of this year.

This data update highlights Day 90+ follow-up data for all patients in parts A and B of the study, and all patients have shown islet cell engraftment and glucose-responsive insulin production. We continue to see all patients demonstrating improved glycemic control across all measures. We also shared more information on three patients who have achieved insulin independence, which is very promising. Check out more details in the press release linked above.

VX-880 is our investigational program for the treatment of T1D that infuses insulin-producing cells into the portal vein of the liver, requiring immunosuppression. This potential treatment is currently being evaluated in a Phase 1/2 multi-part clinical trial for patients with impaired hypoglycemic awareness and severe hypoglycemia (critically low blood sugar levels). You can learn more about T1D and this program on our [Sandbox site](#).

The expansion of our data for VX-880 marks another critical milestone for the program, bringing us one step closer to a potentially curative therapy for patients who are waiting. As we continue to advance our T1D programs, follow [Vertex Sandbox](#) to stay up to date on all the latest news.

Topics

[diabetes research updates](#)[t1d programs](#)[VX-880 program](#)

Send feedback 

Related content